Literature DB >> 2943595

The T lymphocyte response to syngeneic lambda 2 light chain idiotopes. Significance of individual amino acids revealed by variant lambda 2 chains and idiotope-mimicking chemically synthesized peptides.

K Hannestad, G Kristoffersen, J P Briand.   

Abstract

In the present study we have investigated the structure of the helper T cell (Th)-defined idiotope (Id) of myeloma protein 315 lambda 2 light chain (lambda 2(315] in BALB/c (H-2d) mice which carry a high-responder immune response gene for this Id. Three peptides were synthesized which spanned the third hypervariable region (HV3) of lambda 2(315): peptides 88-99, 94-108 and 91-108. Only peptide 91-108 was capable of eliciting carrier-specific Th that recognized M315 or free lambda 2(315). These Th did not recognize lambda 2(5-7) chain which differs from lambda 2(315) at 4 positions in this region; these are Tyr94, Ser95, Thr96, Tyr98 for lambda 2(5-7) and Phe94, Arg95, Asn96, Phe98 for lambda 2(315). Immunization with peptide analogues revealed that substitution of Tyr for Phe94 was compatible with Id-lambda 2(315) mimicry, but substitution of Ser for Arg95 or Thr for Asn96 destroyed the Th-recognized Id. Furthermore, Th primed with lambda 2(5-7) chain did not cross-react with lambda 2T952; these lambda 2 chains only differ from each other at positions 98 and 99 at the V lambda 2-J lambda 2 junction. The data indicate that individual amino acids of short peptide segments are critical for Th-recognized Id of the lambda 2 HV3 loop and V lambda 2-J lambda 2 junction. Furthermore, the immunogenicity of a small peptide suggests that the carrier (lambda 2)-specific Th recognize Id that have been processed by antigen-presenting cells (APC). This implies the existence of two categories of "internal images" of foreign or of self antigens: (a) serologically defined and (b) T lymphocyte defined. We propose that as a rule, Id processing by APC, including B cells, destroys the first and reveals the second category. The possible physiological function of these Id-specific T cells in network interactions with B cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943595     DOI: 10.1002/eji.1830160803

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Genes predisposing to autoimmunity augment constitutive major histocompatibility complex class II-associated presentation of the self-antigen IgG2a in vivo.

Authors:  K Bartnes; X Li; M Iwamoto; S Izui; K Hannestad
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

2.  Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions.

Authors:  Solveig Klaebo Reitan; Kristian Hannestad
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells.

Authors:  S Weiss; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

4.  Working principles in the immune system implied by the "peptidic self" model.

Authors:  P Kourilsky; G Chaouat; C Rabourdin-Combe; J M Claverie
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  Native IgG2a(b) is barely antigenic to major histocompatibility complex class II-restricted T cells owing to inefficient internalization by professional antigen-presenting cells.

Authors:  K Bartnes; K Hannestad
Journal:  Immunology       Date:  2000-04       Impact factor: 7.397

6.  Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule.

Authors:  B Bogen; J D Lambris
Journal:  EMBO J       Date:  1989-07       Impact factor: 11.598

Review 7.  Systemic Lupus Erythematosus: Molecular Mimicry between Anti-dsDNA CDR3 Idiotype, Microbial and Self Peptides-As Antigens for Th Cells.

Authors:  Kristin Aas-Hanssen; Keith M Thompson; Bjarne Bogen; Ludvig A Munthe
Journal:  Front Immunol       Date:  2015-07-28       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.